A snake venom group IIA PLA$_2$ with immunomodulatory activity induces formation of lipid droplets containing 15-d-PGJ$_2$ in macrophages

Karina Cristina Giannotti$^1$, Elbio Leiguez$^2$, Ana Eduarda Zulim de Carvalho$^1$, Neide Galvão Nascimento$^1$, Márcio Hideki Matsubara$^1$, Consuelo Latorre Fortes-Dias$^2$, Vanessa Moreira$^3$ & Catarina Teixeira$^1$

Crotoxin B (CB) is a catalytically active group IIA sPLA$_2$ from Crotalus durissus terrificus snake venom. In contrast to most GIIA sPLA$_2$s, CB exhibits anti-inflammatory effects, including the ability to inhibit leukocyte functions. Lipid droplets (LDs) are lipid-rich organelles associated with inflammation and recognized as a site for the synthesis of inflammatory lipid mediators. Here, the ability of CB to induce formation of LDs and the mechanisms involved in this effect were investigated in isolated macrophages. The profile of CB-induced 15-d-PGJ$_2$ (15-Deoxy-Delta-12,14-prostaglandin J$_2$) production and involvement of LDs in 15-d-PGJ$_2$ biosynthesis were also investigated. Stimulation of murine macrophages with CB induced increased number of LDs and release of 15-d-PGJ$_2$. LDs induced by CB were associated to PLIN2 recruitment and expression and required activation of PKC, PI3K, MEK1/2, JNK, iPLA$_2$ and PLD. Both 15-d-PGJ$_2$ and COX-1 were found in CB-induced LDs indicating that LDs contribute to the inhibitory effects of CB by acting as platform for synthesis of 15-d-PGJ$_2$, a pro-resolving lipid mediator. Together, our data indicate that an immunomodulatory GIIA sPLA$_2$ can directly induce LD formation and production of a pro-resolving mediator in an inflammatory cell and afford new insights into the roles of LDs in resolution of inflammatory processes.

Phospholipases A$_2$ (PLA$_2$s) are enzymes that play a key role in a range of cellular processes in physiological and pathological conditions by regulating the release of arachidonic acid (AA), a precursor of distinct classes of lipid mediators such as prostaglandins and leukotrienes, which are key regulators of inflammatory processes. These enzymes have been classified into fifteen groups (I–XV) and subgroups according to nucleotide and amino acid sequence criteria. The groups comprise five distinct types of enzymes: secreted (sPLA$_2$s), cytosolic (cPLA$_2$s) and calcium independent (iPLA$_2$s) PLA$_2$s, platelet activating factor (PAF) acetylhydrolases and lysosomal PLA$_2$s. Group IIA includes mammalian inflammatory sPLA$_2$s and phospholipases present in vipersid snake venoms. Crotoxin B (CB), a group IIA sPLA$_2$ isolated from Crotalus durissus terrificus (Cdt) snake venom, is one of the two subunits that form crotoxin, the major component of Cdt venom. In contrast to most group IIA sPLA$_2$s, CB per se displays immunomodulatory effects. It is able to inhibit macrophage spreading and phagocytic activities, both of which are associated with increased levels of lipoxin A$_4$ (LXA$_4$), an important arachidonic acid-derived lipid mediator shown to be active in the resolution phase of inflammation. CB also induces the biosynthesis and release of prostaglandin E$_2$ (PGE$_2$) and D$_2$ (PGD$_2$) via activation of the catalytic activity of cyclooxygenase-1 (COX-1). Although PGE$_2$ is known to dilate blood vessels, potentiating edema formation, its immunosuppressive activities, including inhibition of the phagocytic functions and microbicidal activity of macrophages, have been well...
Brewer thioglycolate medium. The animals were killed under CO₂ atmosphere, and the cells were harvested by reversed-phase chromatography, using a 201SP54 column (Grace Vydac, CA, USA). Briefly, 1 mg of CTX CB-induced 15-d-PGJ₂ biosynthesis as well as the involvement of COX-1, COX-2, cPLA₂, iPLA₂ and the signaling processes, we decided to investigate the ability of CB to induce LD formation and the mechanisms involved in LD formation, as well as 15-d-PGJ₂ production, in macrophages. We also investigated the involvement of LDs in CB-induced 15-d-PGJ₂ biosynthesis as well as the involvement of COX-1, COX-2, PLA₂, iPLA₂, and the signaling pathway proteins PI3K, PKC, MEK1/2 and JNK in LD formation.

Materials and Methods

Reagents and chemicals. Hema-3 stain was purchased from Biochemical Sciences Inc. (Swedenboro, NJ, USA). Brewer thioglycolate medium was purchased from Difco, Surrey, UK and RPMI 1640 from Thermo Scientific, Waltham, MA, USA. MTT and L-glutamine were purchased from USB Corporation (Cleveland, OH, USA). H7, SB202190, PD98059, JNK inhibitor II and Pyr-2 were purchased from Calbiochem-Novabiochem Corp. (La Jolla, CA, USA), and racemic BEL, FGGK11, CAL-101, ERK inhibitor, HQL-79 and Valeryl Salicylate from Cayman Chemical (Ann Arbor, MI, USA). SB203580, GFI09203X and SP600125X were purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). U0126, phospho- and total-PKC, -PI3K, -MEK1/2 and -JNK were obtained from Cell Signaling Technology Inc. (Danvers, MA, USA). SC-560 was a kindly supplied by Dr. Alexandre A. Steiner – Dept. of Immunology, ICB, Sao Paulo University, Brazil. Horseradish peroxidase conjugated goat anti-rabbit IgG antibody, mouse monoclonal anti-β-actin antibody and NILE Red were purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). Guinea pig polyclonal anti-mouse PLIN2 antibody and FITC-conjugated donkey anti-guinea pig antibody were purchased from Research Diagnostics Inc. (Flanders, NJ, USA). Secondary anti-mouse and anti-guinea pig horseradish peroxidase conjugated antibodies and nitrocellulose membrane were purchased from GE Healthcare (Buckinghamshire, UK). Gentamicin was purchased from Schering-Plough Corporation (Kenilworth, NJ, USA). DMSO and BSA were purchased from Amresco Inc. (Cleveland, OH, USA). RPMI-1640, thiocarbohydrazide, OsO₄, N-ethyl-N′-(3-dimethylaminopropyl) carbodi-imide hydrochloride (EDAC) and RIPA Buffer (lysis buffer) were purchased from Sigma-Aldrich (Swedenboro, NJ, USA). All the salts used were purchased from Merck KgaA (Darmstadt, Germany). Paraformaldehyde was purchased from Electron Microscopy Sciences (Hatfield, PA, USA). Alexa Fluor 488 goat anti-mouse IgG was purchased from Life Technologies Corporation (Carlsbad, CA, USA) and prostaglandin E₂, prostaglandin J₂ and cyclooxygenase-1 monoclonal antibodies from Cayman Chemical (Ann Arbor, MI, USA). Fluoromount-G was purchased from Molecular Probes (Eugene, OR, USA). Donkey serum was purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA), Triton-X from Union Carbide Corporation (Houston, TX, USA).

Animals. Male Swiss mice (18–20 g) from the Butantan Institute (Sao Paulo, Brazil) were used. The animals were housed in a temperature-controlled room (22–24 °C) with a 12 h light-dark cycle and received fresh water and food ad libitum until they were used. The study was approved by the Butantan Institute Animal Experimentation Ethics Committee (reference no. 846/11) in accordance with the procedures laid down by the Universities Federation for Animal Welfare.

Phospholipase A₂. CB-sPLA₂ was obtained from crotoxin (CTX) isolated from Cdt snake venom by reversed-phase chromatography, using a 201SP54 column (Grace Vydac, CA, USA). Briefly, 1 mg of CTX was loaded onto the column, and fractions of 0.2 mL were eluted with a linear gradient of 0.1% trifluoroacetic acid (TFA) in H₂O and 0.1% TFA in acetonitrile. CTX was isolated from Cdt venom by conventional gel filtration on Sephadex 75. CB identity was checked by SDS-polyacrylamide gel electrophoresis under non-reducing conditions and by matrix-assisted laser desorption ionization time-of-flight mass spectrometry in an AutoFlex III MALDI-TOF-TOF instrument (Bruker Daltonics, Bremen, Germany). The PLA₂ activity of CB was assayed using the classical egg yolk clearing method, which revealed undetectable levels of endotoxin (<0.125 EU/mL).

Macrophage harvesting. Elicited macrophages were harvested four days after i.p. injection of 1 mL of 3% Brewer thioglycolate medium. The animals were killed under CO₂ atmosphere, and the cells were harvested by washing the peritoneal cavities with 3 mL of PBS, pH 7.2, containing 10 IU/mL heparin. Aliquots of the washed
were used for total cell counts in a Neubauer chamber after dilution (1:20, v/v) in Turk’s solution (0.2% crystal violet dissolved in 30% acetic acid). Differential cell counts were performed on smears stained with Hema-3 and examined under light microscopy. More than 95% of the cell population consisted of macrophages according to conventional morphological criteria. The remaining peritoneal wash was centrifuged at 500 g for 6 min (4 °C), and the cell pellets were used for subsequent studies after suitable dilutions.

Cytotoxicity assay. Cytotoxicity of CB and all the pharmacological agents used toward thioglycolate-elicited macrophages was evaluated using a tetrazolium-based assay (MTT). In brief, 2 × 10⁶ macrophages/well in RPMI-1640 medium supplemented with 40 μg/mL gentamicin sulfate and 2 mM L-glutamine were plated in 96-well plates and incubated with 100 μL of selected concentrations of CB (0.1–0.8 μM) diluted in medium or with the same volume of medium alone (control) for 1, 3, 6, 12 or 24 h at 37 °C in a humidified atmosphere of 5% CO₂. MTT (5 mg/mL) was dissolved in PBS and filtered to sterilize it and remove any small amount of insoluble residue present in some batches. Stock MTT solution (10% in culture medium) was added to all wells in each assay, and the plates were incubated at 37 °C for 3 h. Next, a volume of 100 μL of DMSO was added to the wells and mixed thoroughly at room temperature for 30 min. Absorbance at 540 nm was then recorded in a microtiter plate reader. Results were expressed as percentage of viable cells, and the control cells (incubated with medium alone) were considered 100% viable.

Macrophage culture and stimulation. Macrophages were plated on glass coverslips in 24-well plates at a density of 2 × 10⁵ cells/coverslip and allowed to attach for 30 min at 37 °C under a 5% CO₂ atmosphere. Non-adherent cells were removed by washing with PBS. Cell monolayers were cultured for 1 h in RPMI-1640 supplemented with 40 μg/mL gentamicin sulfate and 2 mM L-glutamine at 37 °C and 5% CO₂ and were then challenged with selected concentrations of CB (0.1–0.8 μM) or culture medium alone (control). Where appropriate, the following inhibitors were used: 6 μM H7 or 1 μM GF109203X, both inhibitors of PKC (protein kinase C); 1 μM LY294002 or 1 μM CAL-101, both inhibitors of PI3K (phosphoinositide 3-kinase); 1 μM U73122, an inhibitor of PLC (phospholipase C); 1 μM FIP1, an inhibitor of PLD (phospholipase D); 2 μM JNK inhibitor II or 10 μM SP600125, both inhibitors of JNK (c-Jun N-terminal kinase); 25 μM U0126, an inhibitor of MEK1/2; 5 μM SB203580 or 16 μM SB202190, inhibitors of p38 MAPK (mitogen-activated protein kinase); 25 μM PD98059 or 5 μM ERK inhibitor, both inhibitors of ERK1/2; 2 μM Pyr-2 (Pyrrrolidine-2), an inhibitor of cPLA₂; 2 μM BEL (bromoelanol lactone) or 1 μM FGGK11, both inhibitors of iPLA₂; 30 μM HQL-79, an inhibitor of PGD synthase and 450 μM valeryl salicylate or 0.5 μM SC-560, both inhibitors of COX-1. All the stock solutions were prepared in DMSO and stored at −20 °C. Aliquots were diluted in RPMI-1640 immediately before use to give the required concentration. The final DMSO concentration was always lower than 1% and had no effect on the number of LDs. Pharmacological inhibitors were added 30 or 60 min before stimulation of macrophages with CB or culture medium (control) at concentrations previously tested32–34. Cells treated with the inhibitors were analyzed for viability with the MTT assay. No significant changes in cell viability were registered with any of the above agents or the vehicle at the concentrations used (data not shown).

Lipid droplet staining and quantification. Analysis of LD numbers was performed in osmium-stained cells. In brief, macrophages (2 × 10⁵ cells) adhered to glass coverslips were fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer, pH 7.2, for 15 min and stained with OsO₄ (osmium tetroxide). The coverslips were then rinsed in 0.1 M phosphate buffer, stained in 1% OsO₄ (30 min), rinsed in deionized H₂O, immersed in 10% thiocarbazide (5 min), rinsed again in 0.1 M phosphate buffer, re-stained with 1% OsO₄ (3 min), rinsed with H₂O and then dried and mounted. The morphology of the fixed cells was examined, and round osmiophilic structures were identified as LDs, which were then counted under phase-contrast microscopy using a 100x objective lens in 50 consecutively scanned macrophages in each coverslip. For assays with fluorescent-labeled LDs, macrophages (2 × 10⁵ cells) adhered to glass coverslips were incubated with Nile Red staining solution freshly prepared in 0.1 M phosphate buffer (10 μg/mL) for 20 min at room temperature and washed with phosphate buffer. After several washes the coverslips were mounted with Fluoromount-G and examined under a confocal microscope (Zeiss LSM 510 Meta confocal microscope).

Immunocytochemistry analysis. Detection of PLIN2 in CB-stimulated macrophages was performed by PLIN2 immunostaining. Cells were fixed in 2% PFA, permeabilized with 0.2% Triton-X 100 in 0.1 M phosphate buffer and blocked with 0.5% normal donkey serum in 0.1 M phosphate buffer for 90 min. After PBS washes, macrophages were incubated for 1 h with guinea pig polyclonal anti-mouse PLIN2 (1:2000) diluted in 0.1 M phosphate buffer with 0.2% Triton-X 100. After three washes with PBS (10 min each), the preparations were incubated with secondary FITC-conjugated donkey anti-guinea pig antibody (1:200) in 0.1 M phosphate buffer containing 2% normal donkey serum and 2 mg/mL gentamicin sulfate and 2 mM L-glutamine, and then washed with PBS and incubated with 1% DMSO for 30 min. Coverslips with stained LDs were mounted using Fluoromount-G and examined under a confocal microscope (Zeiss LSM 510 Meta).

Western blotting. For PLIN2 detection, whole cell extracts obtained by lysing the pellets with 100 μL of sample buffer (0.5 M Tris–HCl, pH 6.8, 20% SDS, 1% glycerol, 1 M β-mercaptoethanol, 0.1% bromophenol blue) and boiling them for 10 min were used. Samples were resolved by SDS polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% bis-acrylamide gel overlayed with a 5% stacking gel. Proteins were then transferred
to a nitrocellulose membrane (GE Healthcare, Buckinghamshire, UK) using a Mini Trans-Blot® (Bio-Rad Laboratories, Richmond, CA, USA). The membranes were blocked for 1 h with 5% nonfat dry milk in TTBS (20 mM Tris, 100 mM NaCl and 0.5% Tween 20) and incubated with a primary antibody against PLIN2 (Abcam) overnight at 4 °C or with β-actin (Sigma) for 1 h at room temperature. They were then washed and incubated with the appropriate horseradish peroxidase conjugated anti-rabbit IgG secondary antibody (1:1000 dilution, 1 h, room temperature). To analyze phosphorylated forms of PI3K, MEK1/2, ERK1/2 and JNK, the cells were lysed using RIPA® (Sigma Aldrich) with a protease inhibitor cocktail and phosphatase inhibitors (sodium fluoride 10 mM and sodium orthovanadate 1 mM) and then dissolved (1:5 v/v) in the sample buffer and boiled for 10 min. After the proteins had been separated by SDS-PAGE (12%) and transferred to a nitrocellulose membrane, as described above, the phosphorylated and total non-phosphorylated proteins were detected using polyclonal antibodies to PI3K, MEK1/2, ERK1/2 and JNK (1:1000) and total kinases (1:650) overnight at 4 °C, followed by incubation with horseradish peroxidase-conjugated anti-rabbit IgG (1:1000, 1 h, room temperature). Detection was by the enhanced chemiluminescence (ECL) method according to the manufacturer's instructions (GE Healthcare, Buckinghamshire, UK). Band densities were quantified with a GS 800 Densitometer (Bio-Rad Laboratories, Richmond, CA) using Molecular Analyst® image analysis software (Bio-Rad Laboratories, Richmond, CA).

Quantification of 15-d-PGJ₂ concentrations. 15-d-PGJ₂ (15-deoxy-12,14-PGJ₂) concentrations were determined by a specific enzyme immunoassay using a commercial kit (Enzo life Sciences, Inc. New York, USA) as per manufacturer's protocol.

Statistical Analysis. Data are expressed as the mean ± standard error of mean (SEM) of at least three independent experiments. Multiple comparisons among groups were performed with one-way ANOVA followed by Tukey's test. Probabilities of less than 5% (p < 0.05) were considered statistically significant.

Results

CB induces LDs formation in macrophages. To investigate whether CB would induce formation of LDs in isolated macrophages, these cells were incubated for 1 h with CB at non cytotoxic concentrations ranging from 0.1 to 0.8 µM. Lack of cytotoxicity with these concentrations of CB was previously determined (1–24 h time intervals) by MTT assay. As shown in Fig. 1A, incubation of macrophages for 1 h with CB at concentrations ranging from 0.2 to 0.8 µM, but not 0.1 µM, induced a significant increase in the number of LDs compared with control cells incubated with culture medium alone. Maximal LD numbers were observed with a concentration of 0.8 µM. This CB-induced effect was not observed in Ca²⁺-free, EGTA-containing medium, in a medium in which Ca²⁺ had been replaced by Sr²⁺ or when CB was inactivated by p-bromophenacyl bromide (p-BPB) (Fig. 1B), indicating that the catalytic activity of this sPLA₂ is essential for induction of LD formation under the present experimental conditions. To determine the time-course of CB-induced LD formation, a submaximal concentration of 0.4 µM, and the number of LDs after 1–24 h of incubation was determined. As shown in Fig. 1, CB caused a significant increase in the number of LDs after 1–24 h incubation compared with control cells. The greatest number of LDs was detected after 12 h of incubation (Fig. 1C). As illustrated in Fig. 1D, control macrophages stained with OsO₄ showed very few inclusions in the cytosol. In contrast, the cytosol in CB-stimulated macrophages was packed with the osmiophilic organelles, which can be seen as dark punctate structures in Fig. 1E, F and G. Taken together, these findings indicate that CB is able to induce LD biogenesis in cultured macrophages in a rapid-onset effect that is dependent on the incubation time and catalytic activity of this enzyme.

CB induces protein expression of PLIN2 and its recruitment to LDs in macrophages. PLIN2 is a fatty acid-binding protein that plays an important role in LD assembly and the development of foamy macrophages. In an attempt to better understand the stimulatory effect of CB that leads to LD formation in macrophages, we investigated whether CB induces expression of PLIN2. While this revealed increased levels of PLIN2 expression in cell extracts stimulated with CB for 1, 3 and 12 h, but not for 6 and 24 h, extracts from unstimulated cells (controls) failed to show significant levels of PLIN2 for any of the incubation periods tested (Fig. 2A, B and Supplementary Fig. S1). These findings demonstrate that CB is able to up-regulate PLIN2 expression at translational levels and suggest a mechanism for the increase in LB formation detected in CB-stimulated macrophages. Considering that the increase of PLIN2 protein expression occurred since the first hour of stimulation by CB it is possible that the amount of PLIN2 needed to supply the increased assembly of LDs induced by CB was enough at 6 h of stimulation leading to the transient lack of increase of PLIN2 protein expression seen at 6 h of stimulation by this sPLA₂. At 24 h, however, the absence of PLIN2 protein expression was accompanied by a significant decay of LD numbers, suggesting that CB-induced effect falls into decline. To further identify the mechanisms involved in CB-induced LD formation, the ability of CB to recruit PLIN2 into cytosol LDs was investigated. As illustrated in Fig. 2C, macrophages stimulated with CB (0.4 µM) for 3 h exhibited strong fluorescent staining (green) for PLIN2 with a punctate cytoplasmic pattern that was absent in the unstimulated control cells. Fluorescent Nile Red-labeled neutral lipid inclusions (LDs) overlapping with stained cytoplasmic PLIN2 were also visualized 3 h after CB-induced stimulation indicating that PLIN2 co-localizes to LDs. As expected, no significant staining was detected in control macrophages. These data demonstrate the ability of CB to recruit PLIN2 from cell membranes to form new LDs in macrophages.

Distinct signaling pathways are involved in CB-induced LD formation. Regulation of LD formation induced by diverse inflammatory agents involves stimulus-specific signaling pathways. Participation of protein kinases in the signaling triggered by sPLA₂ has been previously reported. Therefore, the critical signaling proteins involved in CB-induced LD biogenesis were investigated using pharmacological approaches. The effects of selected pharmacological treatments were evaluated 3 h after incubation of macrophages with CB.
To investigate the role of PKC and PI3K in CB-induced LD formation, macrophages were treated with selective PKC and PI3K inhibitors (H7, GF109203X and LY294002, CAL101, respectively) or their vehicles (controls) prior to incubation with CB, followed by quantification of osmium-stained LDs. As seen in Fig. 3A and B, both PKC inhibitors (H7 and GF109203X) and PI3K inhibitors (LY294002 and CAL101) abolished the increased LD formation in CB-stimulated macrophages compared with vehicle-treated CB-stimulated macrophages. Next, we investigated whether the effect of CB on LD formation is related to MAPKs p38 MAPK, ERK1/2 or JNK. As demonstrated in Fig. 3C and D, neither ERK1/2 inhibitors (PD98059 and ERK inhibitor), nor p38 MAPK inhibitors (SB202190 and SB203580) changed the number of LDs in CB-stimulated macrophages compared with vehicle-treated cells. Furthermore, pharmacological inhibition of cells with JNK inhibitors (JNK inhibitor II and SP600125) abolished LD formation in CB-stimulated macrophages compared with untreated control cells. The next protein evaluated was MEK1/2, an important upstream protein of the MAPK signaling pathway. U0126, a MEK1/2 inhibitor, reduced the increase in LD formation in CB-stimulated macrophages compared with vehicle-treated control cells (Fig. 3E), reinforcing the role of the MAPK family in CB-induced LD formation in macrophages. Activation of the proteins PKC, PI3K, MEK1/2 and JNK was confirmed by evaluating the extent of phosphorylation (Fig. 4A, B, C and D). CB induced a significant increase in phosphorylation of these proteins only at the 5-minute time point.

**Figure 1.** CB induces LD formation in peritoneal macrophages. (A) Effect of CB on LD formation in macrophages incubated with selected concentrations of CB or with RPMI (control) for 1 h. (B) Effect of catalytically active CB on LD formation in peritoneal macrophages incubated with one of the following for 1 h: (i) CB (0.4 μM) in a medium containing EGTA (200 μM) with or without Ca²⁺; (ii) CB (0.4 μM) in a medium in which Ca²⁺ was replaced by Sr²⁺; or (iii) RPMI alone (control). (C) Time-course of CB-induced LD formation. Macrophages were incubated with CB (0.4 μM) or RPMI (control) for 1, 3, 6, 12 or 24 h. LDs were quantified using light microscopy after OsO₄ staining. (D) Osmium-stained LDs observed in control cells or in cells stimulated with CB (0.4 μM) for 1 h (E), 6 h (F) or 12 h (G). Each bar represents the mean ± SEM of the number of LDs/cell in 50 cells. Values represent mean ± SEM for three to five animals. *p < 0.05 compared with RPMI-stimulated cells; & p < 0.05 compared with cells stimulated with CB for 1 h, #p < 0.05 compared with cells stimulated with CB for 1, 3 and 6 h, °p < 0.05 compared with cells stimulated with CB for 12 h, and + p < 0.05 compared with CB/Ca²⁺-stimulated cells.
PLD and iPLA₂ are involved in CB-induced LD formation in macrophages. It has been reported that phospholipase D (PLD) and phospholipase C (PLC) play important roles in the signal transduction pathways associated with LD formation. As seen in Fig. 5A, pre-treatment of macrophages with U73122, an inhibitor of PLC, did not have an effect on CB-induced LD formation in comparison with control cells. However, when the cells were incubated with compound FIPI, an inhibitor of PLD (Fig. 5B), LD formation induced by CB was abrogated compared with controls. These results indicate that PLD is critical for the stimulatory effect of CB on LDs formation in macrophages, whereas PLC does not contribute to this CB-induced effect. Additionally, it is known that the intracellular PLA₂s, such as calcium independent PLA₂ (iPLA₂) and cytosolic PLA₂ (cPLA₂) have a role in LDs formation. Moreover, a cross talk between sPLA₂s and intracellular PLA₂s for production of prostaglandins and LDs has been described. Therefore, to verify whether iPLA₂ and/or cPLA₂ would be committed to CB-induced LD formation, macrophages were treated with low micromolar concentrations of Pyr-2, a specific inhibitor of cPLA₂, or with either BEL or FKGK11, both inhibitors of iPLA₂. As shown in Fig. 5C, treatment of macrophages with BEL or FKGK11, but not Pyr-2, caused a significant reduction in the number of LDs in CB-stimulated macrophages compared with CB-stimulated vehicle-treated cells. These data indicate that iPLA₂, but not cPLA₂ plays a role in LD formation induced by CB in macrophages.

CB induces production of 15-d-PGJ₂ via COX-1 in macrophages. 15-d-PGJ₂, which is a PGD₂-derived prostanoid, has been described as a pro-resolving lipid mediator, which is involved in the switch
from the acute into the regenerative phases of inflammation. We have previously reported that CB elicits production of high levels of PGD₂ by isolated macrophages. On this basis, we evaluated the ability of CB to induce the release of 15-d-PGJ₂ from macrophages in culture. 15-d-PGJ₂ concentration was measured in supernatants from macrophages incubated with either a sub-cytotoxic concentration of CB (0.4 μM) or RPMI alone (control). As shown in Fig. 6A, incubation of macrophages with CB induced a significant increase in 15-d-PGJ₂ concentration in the supernatants from 1 up to 24 h, with levels ranging from 1545 ± 149.5 to 2283 ± 340.5 pg/mL (*p < 0.05). The corresponding control values ranged from 110.1 ± 11.5 to 1333 ± 179.3 pg/mL. These results are evidence of the ability of CB to induce generation of 15-d-PGJ₂. Considering that (i) cyclooxygenases are key enzymes in the prostaglandin biosynthetic pathway and (ii) previous data from our group showing that COX-1,
but not COX-2 is activated by CB in macrophages, the effect of inhibitors of COX-1 on CB-induced biosynthesis of 15-d-PGJ₂ was examined. As demonstrated in Fig. 6B, 1 h pretreatment of macrophage cultures with valeryl salicylate (450 μM) or SC-560 (0.5 μM), both specific COX-1 inhibitors, abolished 15-d-PGJ₂ release induced by CB after 3 h and 12 h of incubation in comparison with control cells, pretreated with vehicle and stimulated with CB, indicating participation of COX-1 isoform in the synthesis of 15-d-PGJ₂ induced by CB. In addition, we evaluated the participation of PGD synthase coupled to COX-1 in CB-induced 15-d-PGJ₂ release. As shown in same Fig. (6B), 1 h pretreatment of macrophage cultures with HQ compound (30 μM), a prostaglandin D synthase (PGDS) inhibitor, abolished 15-d-PGJ₂ release induced by CB at 3 and 12 h of incubation in comparison with control cells, pretreated with vehicle and stimulated with CB, confirming the role of PGD₂ as the precursor of 15-d-PGJ₂ in the present experimental condition.

Cytoplasmic LDs in CB-stimulated macrophages compartmentalize 15-d-PGJ₂ and COX-1 and drive 15-d-PGJ₂ production. LDs are known to be organelles associated with the synthesis and storage of inflammatory mediators in immunocompetent cells, such as macrophages. In order to investigate the

**Figure 4.** CB induces PKC, PI3K, MEK1/2 and JNK activation in isolated macrophages. Macrophages were incubated with CB (0.4 μM) or RPMI (control) for 1 or 5 min. Western blotting of total and phospho-PKC (A), total and phospho-PI3K (B), total and phospho-MEK1/2 (C), total and phospho-JNK (D) and β-actin (loading control) in macrophage extracts. Densitometric analysis of the phosphorylated protein bands (E, F, G and H). The densities (in arbitrary units) were normalized with those of β-actin. Results are expressed as mean ± SEM for three experiments. *p < 0.05 compared with RPMI-stimulated cells.
possible role of CB-induced LDs as intracellular sites for the synthesis of lipid mediators, specially 15-d-PGJ2, macrophages stimulated or not by CB were incubated with EDAC to immobilize the newly synthesized eicosanoids45 and immunostained with antibodies against 15-d-PGJ2 and against COX-1, and LDs were stained with Nile Red. As illustrated in Fig. 7A, macrophages stimulated with CB (0.4 \( \mu \)M) for 3 h exhibited a (green) cytoplasmic staining pattern for 15-d-PGJ2. This pattern was not observed in the unstimulated control cells, which exhibited diffuse staining. Fluorescent Nile Red-labeled LDs were also visualized 3 h after stimulation by CB and were virtually absent in unstimulated control macrophages. Overlapping images show that stained cytoplasmic 15-d-PGJ2 matched perfectly with neutral lipid inclusions in CB-stimulated macrophages indicating that 15-d-PGJ2 co-localizes to LDs. In light of our present results showing that formation of LDs induced by CB was inhibited by PKC and JNK, the role of LDs in the synthesis of 15-d-PGJ2 induced by CB was further investigated pretreating macrophages with either PKC inhibitors (H7 and GF109203X) or JNK inhibitors (JNK inhibitor II and SP600125), which abolished CB-induced LD formation, or their vehicles (controls) prior to incubation with CB for 3 h, followed by quantification of 15-d-PGJ2 levels in cell supernatants. As seen in Fig. 7B, treatment of cells with PKC inhibitors abolished the increased 15-d-PGJ2 production in CB-stimulated macrophages compared with untreated control cells. In addition, as illustrated in Fig. 8A, macrophages stimulated with CB (0.4 \( \mu \)M) for 3 h exhibited a punctate cytoplasmic fluorescence (green) for COX-1. This pattern could not be observed in the unstimulated control cells, in which diffuse staining was observed. Fluorescent Nile Red-labeled LDs were also visualized 3 h after stimulation by CB and were virtually absent in unstimulated control macrophages. Overlapping images show that stained cytoplasmic 15-d-PGJ2 and COX-1 matched perfectly with neutral lipid inclusions in CB-stimulated macrophages. Considering these results we investigated whether COX-1 contributes to formation of LDs induced by CB. As demonstrated in Fig. 8B, 1 h pretreatment of macrophages cultures with valeryl salicylate (450 \( \mu \)M) or SC-560 (0.5 \( \mu \)M), both specific COX-1 inhibitors, did not affect LDs formation induced by CB after 3 h of stimulation in comparison with control cells, pretreated with vehicle and stimulated...
with CB, indicating that COX-1 is not involved in formation of LDs induced by CB. In the present experimental condition, this isoform is committed to 15-d-PGJ2 synthesis. Taken together these findings indicate that CB has the capability to induce the synthesis of a pro-resolving lipid mediator (15-d-PGJ2) and its compartmentalization, in association with the prostaglandin-forming enzyme COX-1, in LDs. These data indicate the role of LDs as a relevant site for the synthesis and accumulation of 15-d-PGJ2 in macrophages stimulated by CB.

Discussion

Group IIA secreted phospholipases A2 are enzymes whose proinflammatory properties have been well established53, 54. However, CB, a group IIA sPLA2 isolated from Cdt snake venom, interferes with the development of the inflammatory response by blocking important stages in this process, such as leukocyte recruitment and macrophage activation4, 5. In the present study, the ability of this GIIA sPLA2 to directly stimulate formation of LDs in macrophages and the mechanisms involved in this phenomenon were demonstrated. This effect was time-dependent, had a very fast onset with a maximum at 12 h, and persisted up to the 24-hour time-point. These data agree with previous reports from our group showing that two proinflammatory secreted PLA2s from Bothrops snake venom are able to induce LD formation in isolated macrophages 47, 48. These results are interesting as formation of this organelle in leukocytes is generally associated with a variety of phlogistic stimuli 13, 55, 56, including stimuli by proinflammatory group IIA sPLA2s47, 48. In addition, to our knowledge, this is the first study showing that LD formation can be induced by group IIA sPLA2 that does not induce an inflammatory response.

PLIN2 is a LD marker protein and plays an important role in LD assembly and foam cell formation4–6 by its properties to bind lipids with high affinity and increase the uptake of long chain fatty acids57. Several studies have shown that PLIN2 expression has been directly related to enhanced neutral lipid storage and biogenesis of LDs in a variety of cell types13, 21, 46, 47. Our results show that CB induces PLIN2 recruitment from its membrane pools, suggesting a role for this protein as a nucleation site for formation of new LDs under the stimulus by this sPLA2. Moreover, up-regulation of PLIN2 expression observed within 12 h of stimulation by CB suggests a mechanism for LD formation in CB-stimulated macrophages. These results differ from those obtained with MT-III, a pro-inflammatory PLA2, isolated from Bothrops snake venom, which induced an increase in PLIN2 protein expression in macrophages only 6 h after they were stimulated47.

Next, we investigated the mechanisms by which CB stimulates LD formation in macrophages by focusing on major downstream signaling protein kinases that have previously been shown to participate in LD biogenesis.
induced by inflammatory and infectious stimuli. Our results revealed rapid activation of the signaling proteins PKC, PI3K, MEK1/2 and JNK, but not p38 MAPK or ERK1/2, in macrophages activated by CB. While inhibition of PKC, PI3K, MEK1/2 and JNK abolished the CB-induced increase in LD formation, indicating that these signaling proteins contribute to this increase, p38 MAPK and ERK1/2 do not play a role in CB-induced LD formation. In light of these results, it is reasonable to suggest that PKC and PI3K are crucial in LD formation induced by venom sPLA2s since both proteins are involved in LD formation induced by both Crotalus (CB) and Bothrops sPLA2s (MT-III and MT-II)\(^{47,48}\). Our finding that CB-induced LD formation requires activation of the PI3K pathway is in accordance with data in the literature showing that this signaling protein plays a key role in pathways that up-regulate proteins associated with lipid accumulation such as peroxisome proliferator-activated receptor-gamma (PPAR-\(\gamma\)) and PLIN2\(^{58,59}\). In this context, our finding that CB-induced LD formation in macrophages is largely dependent on both the MEK1/2 and JNK pathways agrees with the literature, which indicates that MEK1/2 and JNK are important signaling proteins implicated in foam-cell formation\(^{60,61}\).

The literature shows that group IIA sPLA2s interact with intracellular PLA2s in the biosynthesis of lipid mediators from fatty acids\(^{6}\) and also that LD formation involves the activation of intracellular PLA2s, such as iPLA2 and cPLA2, as well as other classes of intracellular phospholipases, including PLC and PLD\(^{47–50}\). Our finding that inhibition of iPLA2 by BEL and PKGK11 reduced CB-induced LD biogenesis indicates that this intracellular PLA2 contributes to the effect of CB. However, although cPLA2 has been reported to be relevant to LDs formation induced by diverse PAMPs stimuli and a snake venom inflammatory sPLA2\(^{25,47}\), this intracellular PLA2 does not participate in the genesis of LDs induced by CB in macrophages. A recent study showed the important role

**Figure 7.** CB-induced cytoplasmic LDs compartmentalize 15-d-PGJ2. (A) Macrophages incubated with RPMI (control) or CB (0.4 µM) for 3 h were labeled for LDs (Nile Red) and for 15d-PGJ2 (anti-15d-PGJ2 antibody, Cayman Chemical). The merged image shows colocalization of 15-d-PGJ2 to LDs. The pictures are representative of three independent experiments. (B) Treatment of macrophages with PKC inhibitors H7 (6 µM) or GF109203X (1 µM) or (C) with JNK inhibitors JNK inhibitor II (2 µM) or SP600125 (10 µM) for 1 h before stimulation with CB (0.4 µM) or RPMI (control) for 3 h. 15-d-PGJ2 was quantified by specific EIA. Values represent means ± SEM from 3–4 experiments. *\(p<0.05\) as compared with vehicle treated RPMI-stimulated cells, #\(p<0.05\) as compared with vehicle treated CB-stimulated cells.
of iPLA2 in fatty acid metabolism and triacylglycerol formation\(^6^2\). Since CB induces the release of high levels of arachidonic acid in macrophages\(^7\), our data suggest that upon stimulation by CB this fatty acid contributes to the synthesis of triacylglycerol, which in turn is an important component of LDs. However, the mechanism by which CB activates iPLA2 is unknown and will be investigated in future studies by our group. Additionally, our data show that PLD, but not PLC, is an important step in the signaling pathways involved in the CB-induced effect. It has been shown that PLD acts on the membrane lipid phosphatidylcholine to produce the signal molecule phosphatidic acid (PA), which is a negatively charged phospholipid whose small headgroup promotes membrane curvature, allowing lipid accumulation at this local and facilitating the budding of LDs\(^6^3\). In addition, PA can be converted to bioactive lipids, such as diacylglycerol and lysophosphatidic acid\(^6^4\). Therefore, any or all of these mechanisms may act in conjunction to mediate LD formation. This is the first demonstration that a group IIA sPLA2 crosstalks with PLD, activating LD formation. This finding agrees with an earlier study which showed that activation of PLD\(^2\) was induced by a murine group IIA sPLA2, indicating that there is crosstalk between PLA2s and PLD\(^6^5\).

A previous study by our group showed that CB induces production of high levels of PGD\(_2\) by macrophages\(^7\). It is known that PGD\(_2\) can be chemically modified by non-enzymatic dehydration reactions, leading to production of the cyclopentenone prostaglandin 15-deoxy-\(\Delta^15,14\) PGI\(_2\) (15-d-PGI\(_2\)), an important lipid mediator involved in the resolution phase of inflammation\(^11,12\). In line with our previous findings, the results of the present study show that CB-stimulated macrophages release significant amounts of 15-d-PGI\(_2\) at all the time points, in a process dependent on COX-1 pathway and the terminal PGDS. Furthermore, our data show that (i) CB-induced LDs compartmentalizes both COX-1 and 15-d-PGI\(_2\) and (ii) CB-induced 15-d-PGI\(_2\) is abrogated when LD formation

Figure 8. CB-induced cytoplasmic LDs compartmentalize COX-1, but this enzyme is not involved in LDs formation. (A) Macrophages incubated with RPMI (control) or CB (0.4 \(\mu\)M) for 3 h were labeled for LDs (Nile Red) and for COX-1 (anti-COX-1 antibody, Cayman Chemical). The merged image shows colocalization of COX-1 to LDs. The pictures are representative of three independent experiments. (B) Treatment of macrophages with valeryl salicylate (450 \(\mu\)M) or SC-560 (0.5 \(\mu\)M) a COX-1 inhibitors for 1 h, before stimulation with CB (0.4 \(\mu\)M) for 3 h. LDs were counted using light microscopy after osmium staining. Each bar represents the mean \(\pm\) SEM of the number of LDs/cell in 50 cells. Values represent means \(\pm\) SEM for three to five animals. *\(p < 0.05\) compared...
is inhibited by pretreatment of macrophages with inhibitors of PKC and JNK, upstream and downstream signaling proteins, respectively, that were shown to inhibit LD formation induced by CB. In light of these data, and considering that COX-1, but not COX-2, is activated by CB in macrophages and as LDs are important organelles for eicosanoid synthesis, it is reasonable to suggest that CB-induced LDs are sites for 15-d-PGJ2 synthesis via the COX-1 enzymatic system. To our knowledge, this is the first demonstration that LDs induced by a group IIA sPLA2 are equipped with a COX-1 enzymatic system and are involved in synthesis of a lipid mediator implicated in inflammatory resolution, such as 15-d-PGJ2. In addition, it should be noted that release of the anti-inflammatory mediator 15-d-PGJ2 is in line with the immunomodulatory effects of CB and sheds new light on the mechanisms by which whole Crotalus snake venom and CB, its major sPLA2, can reduce or abolish inflammatory events.

In conclusion, our data show that group IIA sPLA2 CB directly activates peritoneal macrophages to form LDs by a mechanism that is dependent on increased expression and distribution of PLIN2 and requires activation of PKC, PI3K, MEK1/2 and JNK. We also showed that this venom sPLA2 crosstalks with iPLA2 and PLD to induce LDs formation. Our results also indicate for the first time that LDs can constitute platforms implicated in the synthesis of anti-inflammatory lipid mediators such as 15-d-PGJ2 in macrophages stimulated by a sPLA2. Therefore, the LDs, classically recognized as relevant organelles of the acute phase of inflammation, can be involved in both development and resolution of the inflammatory process. Finally, our results reinforce previous findings that phospholipases A2 from snake venom can induce LDs formation in immunocompetent cells and afford new insights into the roles of LDs in the inflammatory process.

References
1. Kodlu, I. & Marakami, M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 68–69, 03–58 (2002).
2. Schaloke, R. H. & Dennis, E. A. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 1761, 1246–1259 (2006).
3. Six, D. A. & Dennis, E. A. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim Biophys Acta 1488, 1–19 (2000).
4. Sampaio, S. C., Rangel-Santos, A. C., Peres, C. M., Curi, R. & Cury, Y. Inhibitory effect of phospholipase A2 isolated from Crotalus durissus terrificus venom on macrophage function. Toxicon 45, 671–676 (2005).
5. Zambelli, V. O. et al. Crotoxin alters lymphocyte distribution in rats: Involvement of adhesion molecules and lipooxygenase-derived mediators. Toxicon 51, 1357–1367 (2008).
6. Sampaio, S. C. et al. Lipooxygenase-derived eicosanoids are involved in the inhibitory effect of Crotalus durissus terrificus venom or crotoxin on rat macrophage phagocytosis. Toxicon 47, 313–321 (2006).
7. Moreira, V. et al. Secretory phospholipases A2 isolated from Bothrops asper and from Crotalus durissus terrificus snake venoms induce distinct mechanisms for biosynthesis of prostaglandins E2 and D2 and expression of cyclooxygenases. Toxicon 52, 428–439 (2008).
8. Konopski, Z., Seljelid, R. & Eskeland, T. Cytokines and PGE2, modulate the phagocytic function of the beta-glucan receptor in macrophages. Scand J Immunol 37, 587–592 (1993).
9. Aronoff, D. M., Canetti, C. & Peters-Golden, M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol 173, 559–565 (2004).
10. Serezani, C. H. et al. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am J Respir Cell Mol Biol 37, 562–570 (2007).
11. Gilroy, D. W. et al. Inducible cyclooxygenase-derived 15-deoxy (Delta 12-14)PGJ2, brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB J 17, 2269–2271 (2003).
12. Scher, J. U. & Pillinger, M. H. 15d-PGJ2; the anti-inflammatory prostaglandin? Clin Immunol 114, 100–109 (2005).
13. Bozza, P. T., Melo, R. C. & Bandeira-Melo, C. Leukocyte lipid bodies regulation and function: contribution to allergy and host defense. Pharmacol Ther 113, 30–49 (2007).
14. Yu, W. et al. Co-compartmentalization of MAP kinases and cytosolic phospholipase A2 at cytoplasmic arachidonate-rich lipid bodies. Am J Pathol 152, 759–769 (1998).
15. Yu, W., Cassara, J. & Weller, P. F. Phosphatidylinositol 3-kinase localizes to cytoplasmic lipid bodies in human polymorphonuclear leukocytes and other myeloid-derived cells. Blood 95, 1078–1085 (2000).
16. Nakamura, N. & Fujimoto, T. Adipose differentiation-related protein has two independent domains for targeting to lipid droplets. J Biol Chem 279, 46835–46842 (2004).
17. Paul, A., Chan, L. & Buckel, P. E. The PAT family of lipid droplet proteins in heart and vascular cells. Curr Hypertens Rep 10, 461–466 (2008).
18. Paul, A., Chang, B. H., Li, L., Yechoor, V. K. & Chan, L. Deficiency of adipose differentiation-related protein impairs foam cell formation and protects against atherosclerosis. Circ Res 102, 1492–1501 (2008).
19. London, C., Szalay, C., Tansey, I. T. & Kimmel, A. R. Role of PAT proteins in lipid metabolism. Biochimie 87, 45–49 (2005).
20. D’Avila, H. et al. Neutrophils recruited to the site of Mycobacterium bovis BCG infection undergo apoptosis and modulate lipid body biogenesis and prostaglandin E2 production by macrophages. Cell Microbiol 10, 2589–2604 (2008).
21. Mattos, K. A. et al. Lipid droplet formation in leprosy: Toll-like receptor-regulated organelles involved in eicosanoid formation and Mycobacterium leprae pathogenesis. J Leukoc Biol 87, 371–384 (2010).
22. Krahmer, N., Jr Farese, R. V. & Walther, T. C. Balancing the fat: lipid droplets and human disease. EMBO J 35, 905–915 (2013).
23. Gross, D. A. & Silver, D. L. Cytosolic lipid droplets: from mechanisms of fat storage to disease. Crit Rev Biochem Mol Biol. 49, 304–326 (2014).
24. Guijas, C., Rodriguez, J. P., Rubio, J. M., Balboa, M. A. & Balsinde, J. Phospholipase A2 regulation of lipid droplet formation. Biochim Biophys Acta 1841, 1661–1671 (2014).
25. Rokni, A. J., Baranowska-Bosiacka, I., Gutowka, I. & Chlubek, D. Cytochrome P450 and the eicosanoid pathways. Acta Biochim Pol 61, 639–649 (2014).
26. Řádmark, O., Werz, O., Steinheilber, D. A. & Samuelsson, B. 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim Biophys Acta 1851, 331–339 (2015).
27. Rubsamen, K., Breithaupt, H. & Habermann, E. Biochemistry and pharmacology of the crototoxin complex. Subfractionation and recombination of the crototoxin complex. Arch Pharmak 270, 274–288 (1971).
28. Fortes-Dias, C. L., Lin, Y., Ewell, J., Diniz, C. R. & Liu, T. Y. A phospholipase A2 inhibitor from the plasma of the South American rattlesnake (Crotalus durissus terrificus). Protein structure, genomic structure, and mechanism of action. J Biol Chem 269, 15646–15651 (1994).
30. Soares, A. M. et al. Effects of chemical modifications of crotonin B, the phospholipase A2 subunit of crotonin from Crotalus durissus terrificus snake venom, on its enzymatic and pharmacological activities. Int J Biochem Cell Biol 33, 877–888 (2001).
31. Takayama, K. et al. Monomerically isolated lipopolysaccharide from Escherichia coli is more active than the aggregated form in the Limulus amebocyte lysate assay and in inducing Egr-1 mRNA in murine peritoneal macrophages. J Biol Chem 269, 2241–2244 (1994).
32. Zhou, Z., Yin, X., Guo, D. P., Hajjar, D. P. & Han, J. Inhibition of ERK1/2 and activation of liver X receptor synergistically induce the expression of ABCA1 expression and cholesterol efflux. Journal of Biological Chemistry 285, 6316–6326 (2010).
33. Zhu, X. et al. Increased Cellular Free Cholesterol in Macrophage-specific Abca1 Knock-out Mice Enhances Pro-inflammatory Response of Macrophages. The Journal of Biological Chemistry 283, 22930–22941 (2008).
34. Cheeseman, K. L. et al. Targeting of protein kinase C-epsilon during Fcgamma receptor-dependent phagocytosis requires the epsilon/CIB domain and phospholipase C-gamma1. Mol Biol Cell. 17, 799–813 (2005).
35. Faugere, D., Chouinard, F. C., Harbour, D., El Azreq, M. A. & Bourgoin, S. G. An essential role for phospholipase D in the recruitment of vesicle amine transport protein-1 to membranes in human neutrophils. Biochem Pharmacol. 81, 144–156 (2011).
36. Wang, L. et al. Mechanical strain inhibits airway smooth muscle gene transcription via protein kinase C signaling. Am J Respir Cell Mol Biol. 31, 54–61 (2004).
37. Srivastava, K., Sampson, H. A., Sr Emala, C. W. & Li, X. M. The anti-asthma herbal medicine ASHMI acutely inhibits airway smooth muscle contraction via prostaglandin E2 activation of EP2/EP4 receptors. Am J Physiol Lung Cell Mol Physiol. 305, L1002–1010 (2013).
38. Mouchemore, K. A. et al. Specific inhibition of PTKK p110e inhibits CSF-1 induced macrophage spreading and invasive capacity. FEBS J. 280, 5228–5236 (2013).
39. Zhang, C., Bi, Y., Jin, G., Gan, H. & Yu, L. High and fluctuating glucose levels increase the expression and secretion of interleukin-18 in mouse peritoneal macrophages. Mol Med Rep. 12, 2715–2720 (2015).
40. Shi, Q. et al. The p38 MAPK inhibitor SB203580 differentially modulates IL-1 interleukin 6 expression in macrophages. Cent Eur J Immunol. 40, 276–282 (2015).
41. Araújo-Santos, T. et al. Role of prostaglandin F2, production in lipid bodies from Leishmania infantum chagasi: insights on virulence. J Infect Dis. 210, 1951–1961 (2014).
42. Mattos, K. A. et al. TLR6-driven lipid droplets in Mycobacterium leprae-infected Schwann cells: immunoinflammatory platforms associated with bacterial persistence. J Immunol. 187, 2548–2558 (2011).
43. Pacheco, P. et al. Monocyte Chemoattractant Protein-1/CC Chemokine Ligand 2 Controls Microtubule-Driven Biogenesis and Leukotriene B4-Synthesizing Function of Macrophage Lipid Bodies Elicited by Innate Immune Response. The Journal of Immunology 179, 8300–8308 (2007).
44. Palise, A. et al. Group VIA phospholipase A2 is a target for vasopressin signaling in the thick ascending limb. Am J Physiol Renal Physiol. 302, F865–874 (2012).
45. Bandeira-Melo, C., Weller, P. F. & Bozza, P. T. EicosaCell - an immunofluorescent-based assay to localize newly synthesized eicosanoid lipid mediators at intracellular sites. Methods Mol Biol 869, 163–181 (2011).
46. Bozza, P. T. & Bandeira-Melo, C. Mechanisms of leukocyte lipid body formation and function in inflammation. Mem Inst Oswaldo Cruz 100, 113–120 (2005).
47. Leiguez, E. et al. A group IIA-secreted phospholipase A2 from snake venom induces lipid body formation in macrophages: the roles of intracellular phospholipases A2 and distinct signaling pathways. J Leukoc Biol 90, 155–166 (2011).
48. Giannotti, K. C. A Lys49 phospholipase A2, isolated from Bothrops atrox venom, is more active than the aggregated form in the Limulus amebocyte lysate assay and in inducing Egr-1 mRNA in murine peritoneal macrophages. J Biol Chem 287, F865–F874 (2012).
49. Wu, J. et al. The molecular mechanism of acylation stimulating protein regulation of adipophilin and perilipin expression: involvement of phosphoinositide 3-kinase and phospholipase C. J. Cell Biochem. 112, 1622–1629 (2011).
50. Barberis, L. & Hirsch, E. Targeting phosphoinositide 3-kinase gamma to fight inflammation and more. J. Cell Biochem. 109, 807–892 (2013).
51. Bozza, P. T., Payne, J. L., Goulet, J. L. & Weller, P. F. Mechanisms of platelet activating factor-induced lipid body formation: requisite roles for 5-lipoxygenase and de novo protein synthesis in the compartmentalization of neutrophil lipids. J. Exp. Med. 183, 1515–1525 (1996).
52. Gubern, A. et al. Group VIA phospholipase A2 is necessary for the biogenesis of lipid droplets. J. Biol. Chem. 283, 27369–27382 (2008).
53. Serhan, C. N. & Devchand, P. R. Novel antiinflammatory targets for asthma. A role for PPARgamma? Am J. Respir. Cell Mol. Biol. 24, 658–661 (2001).
54. Fernandez-Bustamante, A. et al. Early Increase in Alveolar Macrophage Prostaglandin 15d-PGJ2 Precedes Neutrophil Recruitment into Lungs of Cytokine-Insulflated Rats. Inflammation 36, 1030–1040 (2013).
55. Haapamaki, M. M., Gronroos, J. M., Nurmi, H., Alanen, K. & Nevalainen, T. J. Gene expression of group II phospholipase A2 in intestine in Crohn’s disease. Am J Gastroenterol 94, 713–720 (1999).
56. Rosengren, B., Jönsson-Rylander, A. C., Peilot, H., Camejo, G. & Hurt-Camejo, E. Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis. Biochem. Biophys. Acta. 1761, 1301–1308 (2006).
57. Gubern, A. et al. Lipid bodies in inflammatory cells: structure, function, and current imaging techniques. J. Histochem. Cytochem. 59, 340–356 (2011).
58. Gubern, A. et al. Lipid droplets in leukocytes: Organelles linked to inflammatory responses. Exp Cell Res. 340, 193–197 (2016).
59. Gao, J. & Sererro, G. Adipose differentiation related protein (ADRP) in transected COS-7 cells selectively stimulates long chain fatty acid uptake. J. Biol. Chem. 274, 16825–16830 (1999).
60. Barberis, L. & Hirsch, E. Targeting phosphoinositide 3-kinase gamma to fight inflammation and more. Thromb. Haemost. 99, 279–285 (2008).
61. Wu, J. et al. The molecular mechanism of acylation stimulating protein regulation of adipophilin and perilipin expression: involvement of phosphoinositide 3-kinase and phospholipase C. J. Cell Biochem. 112, 1622–1629 (2011).
62. Ricci, R. et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherosclerosis. Science 306, 1558–1561 (2004).
63. Leonarduzzi, G. et al. Oxidation as a crucial reaction for cholesterol to induce tissue degeneration: CD36 overexpression in human promonocytic cells treated with a biologically relevant oxysterol mixture. J. Exp. Med. 207, 32359–32369 (2009).
64. Bigay, J. & Antonny, B. Curvature, lipid packing, and electrostatics of membrane organelles: defining cellular territories in determining specificity. Dev Cell. 23, 896–895 (2012).
65. Jenkins, G. M. & Frohman, M. A. Phospholipase D: a lipid centric review. Cell Mol Life Sci. 62, 2305–2316 (2005).
66. Ueno, N., Murakami, M. & Kudo, I. Functional crosstalk between phospholipase D2 and signaling phospholipase A2/cyclooxygenase-2 mediated prostaglandin biosynthetic pathways. FEBS Lett. 475, 242–246 (2000).
67. Da Silva, N. G., Sampaio, S. C. & Gonçalves, L. R. Inhibitory effect of Crotalus durissus terrificus venom on chronic edema induced by injection of bacillus Calmette-Guérin into the footpad of mice. Toxicon 63, 98–103 (2013).
Acknowledgements
This study was supported by research grant from the Fundação de Amparo à Pesquisa do Estado de Sao Paulo (FAPESP) Brazil (Grant 11/21341-5) and Instituto Nacional de Ciencia e Tecnologia em Toxinas (INCTTOX) Brazil (Grant 08/57898-0). CT was recipient of CNPq-PQ (Grant 306920/2011-5), K.G. is recipient of a PhD fellowship from FAPESP (grant 13/22610-5) and E.L. is recipient of Postdoctoral fellowship from FAPESP, Brazil (Grant 15/247013). The authors thank to Renata Hage do Amaral for providing technical assistance and Dr. Henrique Krambeck Rofatto (FAPESP 00/11624-5, Butantan Institute, Brazil) for helping with the confocal laser scanning microscopy analysis.

Author Contributions
Conceived and designed the experiments: C.T., K.C.G. and E.L. Performed the experiments: K.C.G., E.L., N.G.N., A.E.Z.C., V.M. and M.H.M. Isolated and purified CB: C.L.F.D. Analysed the data: K.C.G., E.L., N.G.N., A.E.Z.C., V.M., M.H.M., C.L.F.D. and C.T. Contributed for reagents/materials/analysis tools: C.T. Wrote the paper: K.C.G., E.L., V.M., C.L.F.D. and C.T. All authors approved the final version.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-04498-8

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017